Cantor Fitzgerald increased its price target for Cypherpunk Technologies to $4.90. This revision represents a significant rise from the previous $1.60 target. The firm maintained its overweight rating, implying a 100% upside from the last closing price.
The company develops novel cancer therapies while managing a digital asset treasury. This dual focus combines biotechnology with financial technology.
The stock has experienced high volatility and increased trading activity since mid-August. Despite the upgrade, the overall analyst consensus remains a Hold.